Chronic Diseases and Translational Medicine 2019;5(3):155-169

Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy

Li BIN-BIN 1 ; Wang BO ; Zhu CHENG-MING ; Tang DI ; Pang JUN ; Zhao JING ; Sun CHUN-HUI ; Qiu MIAO-JUAN ; Qian ZHI-RONG

Affiliations

+expand

Keywords

THZ1; Cyclin-dependent kinase 7; Cancer therapy; Transcription; Super-enhancer

Country

China

Language

English

Abstract

Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs. Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies. In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types. By introducing the anti-tumor behaviors and the po-tential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms.